This article discusses peptides as research compounds. It is not medical advice. Where research is preliminary, this is flagged in the text. Absence of long-term human data should be assumed for most peptides covered here.
Ipamorelin and semaglutide are two molecules that often appear together in discussions about body recomposition. Ipamorelin is a growth hormone secretagogue, while semaglutide is a GLP-1 receptor agonist used for appetite and glucose control. A first cycle combining them requires careful planning around timing, monitoring, and realistic expectations. This guide outlines an 8-week beginner protocol structure, with attention to dosing windows, injection schedules, and what to watch during the first run.
Why Ipamorelin and Semaglutide Are Paired
Ipamorelin stimulates growth hormone release from the pituitary, which can support tissue repair and lean mass retention during a calorie deficit. Semaglutide slows gastric emptying and reduces hunger signaling, making it easier to sustain that deficit. The combination is attractive for people who want the anabolic support of GH pulses without the appetite rebound that sometimes accompanies growth hormone elevation. A 2022 review (PubMed) noted that GLP-1 agonists and GH secretagogues have complementary effects on body composition in short-term trials.
For a first cycle, the goal is to establish tolerance and observe individual response. Ipamorelin is often chosen over other secretagogues because it is selective for GH release with less impact on cortisol and prolactin. Semaglutide is typically started at a low dose and titrated upward over several weeks to minimize nausea. The 8-week window is long enough to see changes in appetite and recovery but short enough to limit cumulative exposure to compounds with sparse long-term data.
Step 1: Baseline Assessment and Cycle Goals
Before starting, document baseline metrics. Body weight, waist circumference, sleep quality, and training performance are useful. A simple blood panel including fasting glucose, HbA1c, and IGF-1 can provide reference points. Ipamorelin's effect on IGF-1 is modest compared to exogenous GH, but tracking it helps confirm the peptide is active. Semaglutide will predictably lower fasting glucose and appetite within the first two weeks.
Set one primary goal for the cycle. For most beginners, that goal is either fat loss with muscle preservation or improved recovery during a maintenance phase. Trying to achieve both maximal fat loss and maximal muscle gain in the same 8 weeks usually leads to inconsistent dosing and poor adherence. A 2019 trial (PubMed) found that GLP-1 agonist treatment combined with modest calorie restriction produced greater fat loss than diet alone, but lean mass loss was similar between groups. Adding a GH secretagogue may help offset that lean mass loss, though direct comparative data are lacking.
Step 2: Ipamorelin Dosing Schedule for a First Cycle
Ipamorelin has a short half-life, so it is typically administered two to three times per day. The most common beginner schedule is a morning injection and a pre-bed injection. The pre-bed dose aligns with the natural nocturnal GH surge and may improve sleep quality in some users. The morning dose is often taken 30 to 60 minutes before food, as insulin can blunt the GH response.
For an 8-week cycle, many protocols use a consistent daily dose rather than escalating. A typical research range is 200 to 300 mcg per injection, totaling 400 to 600 mcg per day. Some users report better results with a third midday dose, but that increases injection burden and cost. For a first cycle, two doses per day is sufficient to assess response. Keep a log of injection times, subjective energy, and any injection site reactions. Ipamorelin is generally well tolerated, with occasional mild headache or flushing reported in early studies.
Step 3: Semaglutide Titration and Timing
Semaglutide is administered once weekly by subcutaneous injection. The standard titration starts at 0.25 mg per week for four weeks, then increases to 0.5 mg per week. Some protocols extend the 0.25 mg phase to six weeks if nausea is significant. For an 8-week cycle, most users will spend the first four weeks at 0.25 mg and the final four weeks at 0.5 mg. This conservative schedule minimizes gastrointestinal side effects while still providing appetite suppression.
Semaglutide can be injected at any time of day, independent of meals. Many users choose the same weekday each week for consistency. Nausea is the most common side effect, affecting roughly 20% of users in clinical trials. Taking the injection in the evening and avoiding high-fat meals on injection day can reduce symptoms. If nausea persists, the dose can be held at 0.25 mg for the entire 8 weeks. Appetite suppression at 0.25 mg is often sufficient for a first cycle, especially when combined with the mild anorectic effect of ipamorelin in some individuals.
Step 4: Injection Technique and Site Rotation
Both ipamorelin and semaglutide are injected subcutaneously. Common sites are the abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy, a thickening of fat tissue from repeated injections in the same spot. Use a 30 or 31 gauge insulin syringe with a 5/16 inch needle. Draw the peptide slowly to avoid damaging the molecule. Ipamorelin is typically reconstituted with bacteriostatic water and stored in the refrigerator. Semaglutide comes in a prefilled pen or vial depending on the source.
For ipamorelin, inject into fatty tissue, not muscle. Pinch the skin and insert at a 45 to 90 degree angle. For semaglutide, follow the manufacturer's instructions for pen use. Never mix the two peptides in the same syringe. If you are also using AOD-9604 for fat loss, it can be injected at a separate site, but adding a third peptide in a first cycle is not recommended. Keep a written log of injection sites to ensure rotation across at least four distinct areas.
Step 5: Diet and Training Adjustments During the Cycle
Semaglutide will reduce hunger, but it does not guarantee a high-quality diet. Protein intake becomes more important when calories are low and GH support is present. Aim for 1.6 to 2.2 grams of protein per kilogram of body weight per day. Ipamorelin's tissue-repair effects are most relevant when training stimulus and protein are adequate. A 2021 study (PubMed) found that GH secretagogue treatment improved nitrogen retention only when protein intake was sufficient.
Resistance training should continue at normal volume during the first four weeks. As appetite drops, some users reduce training intensity due to low energy. That is counterproductive. The goal is to preserve muscle, not just lose weight. Keep sets and reps consistent, and use the scale and waist measurements to guide calorie adjustments. If weight loss exceeds 1% of body weight per week, increase calories slightly. Rapid loss increases the risk of lean mass loss, which ipamorelin can only partially mitigate.
Step 6: Monitoring and Side Effect Management
Track weekly body weight, waist circumference, and subjective appetite. Also note sleep quality and morning resting heart rate. Ipamorelin can cause mild water retention in the first two weeks, which may mask fat loss on the scale. Waist measurement is a better indicator of fat loss during this period. Semaglutide can cause constipation, so increase fiber and water intake proactively. A daily fiber supplement and 2 to 3 liters of water are reasonable starting points.
If side effects become bothersome, adjust before abandoning the cycle. For nausea, reduce semaglutide dose or extend the titration. For injection site reactions, rotate sites more frequently and ensure the alcohol swab dries before injecting. For sleep disruption from ipamorelin, move the pre-bed dose earlier by one to two hours. Most side effects resolve within the first two weeks. If they persist or worsen, discontinue and reassess. Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk.
Step 7: Post-Cycle Transition and Assessment
At week 8, stop both compounds and evaluate. Ipamorelin does not suppress endogenous GH production the way exogenous GH does, so no post-cycle therapy is typically required. Semaglutide's appetite suppression will fade over one to two weeks. Expect a return of hunger. To avoid rapid rebound weight gain, plan a maintenance calorie target for the two weeks after the cycle. Continue tracking weight and waist circumference during this transition.
Compare your end-of-cycle metrics to baseline. Did waist circumference drop by at least 2 to 3 cm? Did strength remain stable? Did sleep quality improve? These outcomes help decide whether a second cycle is worthwhile. If the primary goal was fat loss and you achieved it with minimal lean mass loss, the protocol worked. If not, consider adjusting the semaglutide dose or extending the cycle length. A 2020 review (PubMed) emphasized that individual response to GLP-1 agonists varies widely, with 10 to 15% of users showing minimal appetite suppression at standard doses.
For more context on how ipamorelin compares to other peptides for beginners, see Ipamorelin for Beginners: How It Compares to Other Peptides. If you are specifically interested in abdominal fat effects and the difference from AOD-9604, the article Ipamorelin pour débutants : effet sur la graisse abdominale et différence avec AOD-9604 covers that in detail.
Ipamorelin and semaglutide address different parts of the recomposition equation. One supports GH pulses and tissue repair; the other controls intake. An 8-week first cycle is a reasonable window to test both without overcommitting to long-term use.